12:00 AM
 | 
Sep 29, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CPI-613: Phase I/II started

Cornerstone began an open-label, dose-escalation, North American Phase I/II trial to evaluate intravenous CPI-613 given twice weekly for...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >